Navigation Links
Nevirapine-based treatment is effective in African women, but not optimal
Date:6/12/2012

Boston, MAAccording to new research from Brigham and Women's Hospital (BWH), an anti-AIDS treatment regimen, which includes the WHO-recommended drug nevirapine, is just as effective at suppressing the HIV virus as lopinavir/ritonavir, which is more expensive. The study is published in the June 12 issue of PLoS Medicine.

These findings are reassuring as they confirm the 2010 recommendation from the World Health Organization (WHO) that initial treatment of HIV-infected women, in resource-limited settings, should be a nevirapine based regimen. This particular combination is rapidly becoming one of the most commonly used antiretroviral treatment regimens worldwide, particularly among women. However, minimal data regarding the efficacy of this combination existed before this study and earlier data raised concerns about the potency of this regimen.

The researchers, led by Shahin Lockman, MD, a physician-researcher in the Division of Infectious Diseases at BWH, conducted one of the larger treatment studies in HIV infected women, worldwide. They analyzed 500 HIV-infected women in Africa who had not previously taken any antiretroviral treatment but who were found to have advanced HIV disease and required treatment. Half of the women received an antiretroviral therapy which contained nevirapine, and the other half received the antiretroviral therapy which contained lopinavir/ritonavir, which is much more expensive and is reserved for second-line treatment in resource limited settings.

The researchers found that the two treatment regimens were equally as effective in suppressing the HIV virus and keeping people alive. However, the major difference in the two treatments was that 14 percent of the women in the nevirapine group stopped treatment because of adverse health effects. None of the women in the lopinavir/ritonavir group stopped treatment.

"Our findings show that the nevirapine based regime is potent and effective, just not optimal," explained Lockman.

Overall, while the study provides some reassurance regarding effectiveness, the results reinforce that other better-tolerated regimes should be sought after and used where possible.

"The take away message of our study should be that while this regimen works, it's not the best that we could be using and we need to continue to press for better access to better regimes," Lockman added.


'/>"/>

Contact: Jessica Maki
jmaki3@partners.org
617-534-1603
Brigham and Women's Hospital
Source:Eurekalert

Related medicine news :

1. Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis
2. Depressed Teens Who Respond to Treatment Less Likely to Abuse Drugs
3. Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
4. Control of disease activity and biologic treatment increase life expectency in RA patients
5. Treatment with anti-TNFs can increase the risk of shingles by up to 75 percent
6. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
7. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
8. Hear to see: New method for the treatment of visual field defects
9. Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment
10. Antioxidant shows promise as treatment for certain features of autism, Stanford study finds
11. Antiretroviral treatment for preventing HIV infection: an evidence review for physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... in order to improve teacher quality, the field must first improve teacher preparation ... popular reform to the next” and that decades of input- and outcome-based research ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield ... Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, and ... estate valuation industry for more than 40 years. , “Ruel is a great ...
(Date:3/28/2017)... ... , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts ... Secret. Dr. Wentz talked about journey and research recently on a blog and discussed ... the only solution to deal with thyroid disease. , Dr. Wentz completed her ...
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of warmer weather ... those self-conscious about a double chin, this means more anxiety than elation. The cosmetic ... “For most people, a double chin is undesirable,” Dr. Goldman said, “but it seems ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 The ... (dupilumab) injection to treat adults with moderate-to-severe eczema ... eczema is not controlled adequately by topical therapies, ... advisable. Dupixent can be used with or without ... demonstrates our commitment to approving new and innovative ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... , Va. and PHOENIX , March 28, ... Avella Specialty Pharmacy released a new white ... allergies and the use of latex in healthcare. Specifically, there ... in healthcare. In fact, the FDA has urged manufacturers to ... latex" claim from labels, because of the challenge to ensure ...
Breaking Medicine Technology: